drugset / Trial / NCT01089621

A Study for Adolescents With Fibromyalgia Syndrome

NCT01089621

Phase 4 Withdrawn Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the possibility of conducting a larger study in adolescents with fibromyalgia syndrome.

Timeline

Start
2010-03
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 30 mg Oral
Subject Duloxetine Small molecule 120 mg Oral

Indications